Document Detail


Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138.
MedLine Citation:
PMID:  17109339     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Although the determinants of immune deficiency and immune restoration in chronic human immunodeficiency virus (HIV)-1 infection are not well understood, immune activation has been proposed as being central to the pathogenesis of HIV. METHODS: A randomized, controlled trial of cyclosporin A treatment for 2 weeks was performed in persons with chronic HIV-1 infection who were beginning a standardized antiretroviral therapy (ART) regimen. RESULTS: Treatment with cyclosporin A provided only a marginal and transient enhancement in circulating T cell restoration that was largely restricted to cells expressing the CCR7 chemokine receptor and that did not persist beyond 2 weeks. CONCLUSIONS: Cyclosporin A coadministered for 2 weeks with ART provided no sustained immunologic benefit to persons with chronic HIV-1 infection. If immune activation drives progressive immune deficiency in chronic HIV-1 infection, these activation pathways may not be sensitive to cyclosporin.
Authors:
Michael M Lederman; Laura Smeaton; Kim Y Smith; Benigno Rodriguez; Minya Pu; Hongying Wang; Anne Sevin; Pablo Tebas; Scott F Sieg; Kathy Medvik; David M Margolis; Richard Pollard; Hildegund C J Ertl; Hernan Valdez
Related Documents :
1364969 - Immunological profile of patients with recurrent respiratory infections.
21663629 - Hcv genotype-specific correlation with serum markers: higher predictability for genotyp...
6432669 - Follow-up of circulating immune complexes in the course of acute viral hepatitis, and c...
24732819 - The kenya aids indicator survey 2012: rationale, methods, description of participants, ...
2146279 - The pathogenesis of hiv infection.
16229679 - The patient: emerging clinical applications of intravenous immunoglobulin.
24641669 - The association between social networks and self-rated risk of hiv infection among seco...
17075339 - New therapeutic options for hepatitis c.
10668839 - Marked declines in human immunodeficiency virus-related mortality in chicago in women, ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2006-11-02
Journal Detail:
Title:  The Journal of infectious diseases     Volume:  194     ISSN:  0022-1899     ISO Abbreviation:  J. Infect. Dis.     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-11-19     Completed Date:  2007-01-17     Revised Date:  2007-12-03    
Medline Journal Info:
Nlm Unique ID:  0413675     Medline TA:  J Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1677-85     Citation Subset:  AIM; IM    
Affiliation:
Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH 44106, USA. MXL6@case.edu
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00031070
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Retroviral Agents / therapeutic use*
Chronic Disease
Cyclosporine / administration & dosage,  therapeutic use*
Drug Administration Schedule
Drug Therapy, Combination
Female
HIV Infections / drug therapy*,  immunology
HIV-1*
Humans
Immunosuppressive Agents / administration & dosage,  therapeutic use*
Lymphocyte Count
Male
Middle Aged
Receptors, Chemokine / biosynthesis
T-Lymphocytes / immunology
Treatment Outcome
Grant Support
ID/Acronym/Agency:
AI 25868/AI/NIAID NIH HHS; AI 25879/AI/NIAID NIH HHS; AI 36219/AI/NIAID NIH HHS; AI 38858/AI/NIAID NIH HHS; AI 50410/AI/NIAID NIH HHS; RR 00046/RR/NCRR NIH HHS; RR 00080/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Retroviral Agents; 0/Immunosuppressive Agents; 0/Receptors, Chemokine; 59865-13-3/Cyclosporine
Comments/Corrections
Comment In:
J Infect Dis. 2006 Dec 15;194(12):1632-4   [PMID:  17109333 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations,...
Next Document:  Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppres...